Obesity Medication Pathway

Following a NICE Technology Approval publication (TA1026) on 23 December 2024, tirzepatide (Mounjaro®) was recommended for use in Primary Care as a new setting of care, for managing obesity, alongside a reduced-calorie diet and increased physical activity in adults. The NHS England Interim Commissioning Guidance outlines the eligibility criteria.

Standardised clinical system resources have been rolled out on a national scale across England for all GP practices through NHS England’s GPIT Providers. These resources support the capture of essential data related to the NICE Funding Variation for the implementation of prescribing of tirzepatide (Mounjaro®) for the management of obesity. The resources are also aligned to the Quality Outcomes Framework (QOF), guidance on how to access these can be found in Resource Access

• Resource Access

• Overview of the Coding Process

• Interim Commissioning Guidance

• Healthcare Professional Training Resources